DMAC (DiaMedica Therapeutics) Cash per Share: $0.95 (As of Mar. 2026)

What is DiaMedica Therapeutics Cash per Share?

DiaMedica Therapeutics DMAC -3.20% 31 Cash per Share is $0.95 as of Mar. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). DiaMedica Therapeutics's Cash per Share for the quarter that ended in Mar. 2026 was $0.95.

DiaMedica Therapeutics (NAS:DMAC) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

DiaMedica Therapeutics Cash per Share Related Terms

DiaMedica Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Cash per Share Chart

DiaMedica Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash per Share

Get a 7-Day Free Trial

1.71

1.27

1.39

1.03

1.11

DiaMedica Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash per Share	Get a 7-Day Free Trial															0.85	0.70	1.06	1.11	0.95

31GF Score

DiaMedica Therapeutics Inc DMAC

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

DiaMedica Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

DiaMedica Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	59.89	/	53.74
	=	1.11

DiaMedica Therapeutics's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	51.331	/	53.88
	=	0.95

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of $0.95 mean?

DiaMedica Therapeutics (DMAC) has a Cash per Share of $0.95 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for DiaMedica Therapeutics and its competitors.

Is DiaMedica Therapeutics' Cash per Share too high?

DiaMedica Therapeutics' current Cash per Share is $0.95. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does DiaMedica Therapeutics' Cash per Share compare to PRLD and RCKT?

DiaMedica Therapeutics' Cash per Share of $0.95 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Biotechnology company?

A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Cash per Share is $0.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is DiaMedica Therapeutics stock overvalued right now?

DiaMedica Therapeutics (DMAC) has a current Cash per Share of $0.95. The current Cash per Share is $0.95. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Cash per Share is $0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies PRLD RCKT TENX AVIR VNDA OABI CYDY UPB VSTM IRD VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305

Website https://www.diamedica.com

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

31GF Score

Get the complete analysis for DMAC

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.71

Price

View DMAC Analysis

See Cash per Share data for all stocks →